ArticleFrontiers in molecular biosciences2026
Metagenomics next-generation sequencing of plasma combined with blood cells for improving the prognosis of early infection in patients with hematologic disorders: a real-world cohort study in northern China.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Infection is a leading cause of death in hematologic disorder patients. While plasma metagenomic next-generation sequencing (mNGS) is widely used, no studies have explored the clinical value of whole blood mNGS, combining plasma and blood cells, in these patients. Methods: We retrospectively analyzed the results of whole blood mNGS testing from 231 blood samples of hematological disorders patients with suspected infections. The diagnostic performance of whole blood mNGS and its clinical impacts on treatment were assessed based on the final clinical diagnosis. Results: mNGS testing in both plasma and whole blood showed significantly higher pathogen detection rates than blood culture (72.29%, 77.06% vs. 21.65%, P < 0.001). The total concordance rate of whole blood mNGS was also significantly higher than that of blood culture, conventional microbial testing, and plasma mNGS when compared to the final clinical diagnosis. Of the 101 pathogens detected by whole blood mNGS, 13 were missed by plasma mNGS. As a result, whole blood mNGS demonstrated a broad pathogen detection capability, especially in patients with non-hematologic malignancies or hematopoietic stem cell transplantation. Regarding treatment, whole blood mNGS had a positive impact on 72.73% of all patients, and 75.15% patients with pulmonary infections. It helped rule out infection in a timely manner, reduce or stop unnecessary antibiotic use, and enabled 77.88% of infected patients to benefit from whole blood mNGS sequencing. Discussion: Whole blood mNGS assays, combining plasma and blood cells, significantly improved pathogen detection rates and optimized antibiotic therapy in patients with hematological diseases and pulmonary infections or bloodstream infection. This approach facilitates the early management of patients with hematologic disorders who are at risk of infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.